logo

For the Inventor, By the Inventor

Burlingame, CA, United States of America

Corvus Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 16


Forward Citations = 9

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Richard A Miller (10 out of 25 patents)

silverMedal Stephen Willingham (5 out of 18 patents)

bronzeMedal Andrew Hotson (5 out of 5 patents)

4.  Ian Mccaffery (5 out of 5 patents)

5.  Ryan Hudson (4 out of 42 patents)

6.  Anne-Marie Beausoleil (4 out of 34 patents)

7.  Emily Piccione Griffin (4 out of 7 patents)

8.  Hwai Wen Chang (2 out of 58 patents)

9.  Gerhard Johann Frey (2 out of 87 patents)

10.  Po Y Ho (2 out of 2 patents)

11.  William Benton Jones (2 out of 2 patents)

12.  Erik J Verner (2 out of 83 patents)

13.  Zhihong Li (1 out of 16 patents)

14.  Jingrong Xu (1 out of 1 patent)

15.  Felicia Flicker (1 out of 1 patent)


16 patents:

1. 12686677 - Compounds and methods for modulating interleukin-2-inducible t-cell kinase (2026-07-21),
2. 12351644 - Anti-CD73 antibodies (2025-07-08),
3. 12174192 - Methods for detecting and treating cancers having adenosine pathway activation (2024-12-24),
4. 12116635 - Methods for detecting and treating cancers having adenosine pathway activation (2024-10-15),
5. 12023337 - Methods of treating cancer (2024-07-02),
6. 11897874 - Compounds and methods for modulating Interleukin-2-inducible T-cell kinase (2024-02-13),
7. 11859007 - Humanized anti-CD73 antibodies (2024-01-02),
8. 11266649 - Pharmaceutical formulations (2022-03-08),
9. 11254686 - Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor (2022-02-22),
10. 11040040 - Methods of treating cancer (2021-06-22),
11. 11008314 - Compounds and methods for modulating interleukin-2-inducible t-cell kinase (2021-05-18),
12. 10912776 - Methods of treating cancer (2021-02-09),
13. 10870652 - Compounds and methods for modulating bruton's tyrosine kinase (2020-12-22),
14. 10822426 - Humanized anti-CD73 antibodies (2020-11-03),
15. 10793636 - Anti-CD73 antibodies (2020-10-06),
Company Overview
Corvus Pharmaceuticals, Inc. is a biopharmaceutical company based in Burlingame, California, focused on developing innovative therapies for cancer treatment. The company specializes in immuno-oncology, leveraging the body's immune system to combat cancer cells. Corvus is dedicated to advancing its pipeline of drug candidates through rigorous research and clinical trials, aiming to address significant unmet medical needs in oncology. Its commitment to scientific excellence drives the development of novel therapeutic approaches to improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

16 Patents

#12 in Burlingame, CA

#4,788 in California

#19,954 in US

#37,914 in the World

Burlingame, CA (US)
Burlingame, CA, United States of America

Corvus Pharmaceuticals, Inc.

Forward Citations = 9

20 inventors:

goldMedal Richard A Miller (10 out of 25 patents)

silverMedal Stephen Willingham (5 out of 18 patents)

bronzeMedal Andrew Hotson (5 out of 5 patents)

4.  Ian Mccaffery (5 out of 5 patents)

5.  Ryan Hudson (4 out of 42 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Corvus Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/corvus-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…